Alameda, CA, United States of America

Jeffrey L Windelhake


Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 20(Granted Patents)


Company Filing History:


Years Active: 1990

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Mind of Jeffrey L. Windelhake

Introduction

Jeffrey L. Windelhake is a notable inventor based in Alameda, California, recognized for his significant contributions to the field of cancer treatment. With a focus on immunotoxins, Windelhake’s work aims to directly combat human ovarian cancer, showcasing the potential of targeted therapies in oncology.

Latest Patents

Windelhake holds a patent titled "Anti-human ovarian cancer immunotoxins and methods of use thereof." This innovative patent describes immunotoxins that feature a cytotoxic moiety combined with monoclonal antibodies. These antibodies specifically bind to human ovarian cancer tissue, demonstrating remarkable capabilities such as a cytotoxic ID.sub.50 of 10 nM or less against human ovarian cancer cells. Additionally, his research claims to retard tumor growth in mammals and extend the survival of those suffering from this severe illness.

Career Highlights

Throughout his career, Windelhake has made strides in the development of therapies that enhance the quality of life for cancer patients. His work with immunotoxins highlights his commitment to advancing medical science and developing targeted cancer therapies. By concentrating on specific antigens and methods for prolonging survival, he has effectively contributed to the medical community’s arsenal against cancer.

Collaborations

Windelhake has collaborated with talented individuals such as Michael J. Bjorn and David J. FitzGerald. Working alongside these noteworthy professionals at Cetus Corporation, Windelhake has been able to nurture a collaborative environment that promotes innovative solutions for tackling some of health care's biggest challenges.

Conclusion

Jeffrey L. Windelhake stands as a testament to the power of innovation in the healthcare sector. His patent on anti-human ovarian cancer immunotoxins not only demonstrates his exceptional ingenuity but also offers hope for improved treatment options for those affected by ovarian cancer. Through his work and collaborations, Windelhake continues to pave the way for future advancements in cancer therapy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…